Wall Street analyst estimates for Baxter International Inc. (BAX): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Baxter International Inc., operating globally via its subsidiaries, is a leading developer and provider of a wide spectrum of healthcare products. The company's comprehensive portfolio includes various dialysis treatments, such as peritoneal and hemodialysis, along with related therapies and services. It also specializes in intravenous (IV) therapies, infusion pumps, administration sets, and devices for drug reconstitution.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-10-29 | $0.52 | ||
| 2026-07-30 | $0.56 | $0.37 | +52.8% |
| 2026-04-30 | $0.36 | $0.31 | +15.8% |
| 2026-02-12 | $0.44 | $0.53 | -17.0% |
| 2025-10-30 | $0.69 | $0.60 | +15.0% |
| 2025-07-31 | $0.59 | $0.60 | -1.7% |
| 2025-05-01 | $0.55 | $0.48 | +13.8% |
| 2025-02-20 | $0.58 | $0.53 | +9.8% |
Valuation Ratios
| Price / Book | 1.96 |
| EV / EBITDA | 23.29 |
| Dividend Yield | 0.17% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10.16B | $10.58B | $11.10B | $11.36B | $11.67B | $12.15B | $10.06B | $10.36B | $10.64B | $11.24B |
| Cost of Revenue | $6.05B | $6.11B | $6.34B | $6.60B | $7.09B | $7.43B | $6.51B | $6.21B | $6.65B | $7.87B |
| Gross Profit | $4.12B | $4.47B | $4.76B | $4.76B | $4.59B | $4.72B | $3.55B | $4.15B | $3.98B | $3.38B |
| Research & Development | $646.0M | $615.0M | $654.0M | $595.0M | $521.0M | $531.0M | $450.0M | $518.0M | $590.0M | $518.0M |
| Selling, General & Admin | $2.73B | $2.63B | $2.62B | $2.54B | $2.47B | $2.85B | $3.10B | $2.95B | $2.97B | $2.89B |
| Operating Expenses | $3.37B | $3.19B | $3.17B | $2.99B | $2.97B | $3.37B | $6.39B | $3.44B | $3.97B | $3.69B |
| Operating Income | $745.0M | $1.29B | $1.58B | $1.77B | $1.62B | $1.35B | -$2.85B | $707.0M | $14.0M | -$308.0M |
| EBITDA | $5.84B | $1.94B | $2.48B | $1.87B | $2.27B | $2.19B | -$1.76B | $1.73B | $1.12B | $766.0M |
| Interest Expense | $89.0M | $85.0M | $93.0M | $111.0M | $153.0M | $207.0M | $413.0M | $508.0M | $408.0M | $290.0M |
| Pre-tax Income | $4.95B | $1.10B | $1.62B | $970.0M | $1.29B | $1.12B | -$3.25B | $242.0M | -$289.0M | -$505.0M |
| Income Tax | -$12.0M | $491.0M | $65.0M | -$41.0M | $182.0M | $83.0M | -$135.0M | $61.0M | $37.0M | $395.0M |
| Net Income | $4.96B | $602.0M | $1.55B | $1.00B | $1.10B | $1.28B | -$2.43B | $2.66B | -$649.0M | -$957.0M |
| EPS | $9.09 | $1.11 | $3.04 | $1.97 | $2.17 | $2.56 | $-4.83 | $5.25 | $-1.27 | $-1.75 |
| EPS (Diluted) | $9.01 | $1.08 | $2.97 | $1.93 | $2.13 | $2.53 | $-4.83 | $5.23 | $-1.27 | $-1.75 |
| Shares Outstanding (Diluted) | $551.0M | $555.0M | $546.0M | $519.0M | $517.0M | $508.0M | $504.0M | $506.0M | $510.0M | $513.0M |
Price
| Price | $23.53 |
| Market Cap | $12.2B |
| Exchange | NYSE |
| Country | US |
Related companies: ATR · AVTR · BIO · DVA · HIMS · MASI · MDGL
Explore sector: Healthcare · Medical - Instruments & Supplies
More sections of BAX: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks